Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 5
2005 5
2006 4
2007 4
2008 5
2009 5
2010 7
2011 11
2012 8
2013 8
2014 7
2015 11
2016 14
2017 23
2018 8
2019 8
2020 10
2021 8
2022 7
2023 9
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Results by year

Filters applied: . Clear all
Page 1
Vemurafenib.
Garbe C, Eigentler TK. Garbe C, et al. Among authors: eigentler tk. Recent Results Cancer Res. 2018;211:77-89. doi: 10.1007/978-3-319-91442-8_6. Recent Results Cancer Res. 2018. PMID: 30069761 Review.
Vemurafenib.
Garbe C, Abusaif S, Eigentler TK. Garbe C, et al. Among authors: eigentler tk. Recent Results Cancer Res. 2014;201:215-25. doi: 10.1007/978-3-642-54490-3_13. Recent Results Cancer Res. 2014. PMID: 24756795 Review.
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
Garbe C, Keim U, Amaral T, Berking C, Eigentler TK, Flatz L, Gesierich A, Leiter U, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zimmer L, Zouboulis CC, Ascierto PA, Eggermont AMM, Grob JJ, Hauschild A, Sekulovic LK, Long GV, Luke JJ, Michielin O, Peris K, Schadendorf D, Kirkwood JM, Lorigan PC; Central Malignant Melanoma Registry (CMMR). Garbe C, et al. Among authors: eigentler tk. J Clin Oncol. 2022 Nov 10;40(32):3741-3749. doi: 10.1200/JCO.22.00202. Epub 2022 Jun 16. J Clin Oncol. 2022. PMID: 35709414 Free PMC article.
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A. Ribas A, et al. Among authors: eigentler tk. Lancet Oncol. 2015 Aug;16(8):908-18. doi: 10.1016/S1470-2045(15)00083-2. Epub 2015 Jun 23. Lancet Oncol. 2015. PMID: 26115796 Free PMC article. Clinical Trial.
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.
Becker JC, Ugurel S, Leiter U, Meier F, Gutzmer R, Haferkamp S, Zimmer L, Livingstone E, Eigentler TK, Hauschild A, Kiecker F, Hassel JC, Mohr P, Fluck M, Thomas I, Garzarolli M, Grimmelmann I, Drexler K, Spillner AN, Eckhardt S, Schadendorf D; DeCOG. Becker JC, et al. Among authors: eigentler tk. Lancet. 2023 Sep 2;402(10404):798-808. doi: 10.1016/S0140-6736(23)00769-9. Epub 2023 Jul 11. Lancet. 2023. PMID: 37451295 Clinical Trial.
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
Livingstone E, Zimmer L, Hassel JC, Fluck M, Eigentler TK, Loquai C, Haferkamp S, Gutzmer R, Meier F, Mohr P, Hauschild A, Schilling B, Menzer C, Kiecker F, Dippel E, Roesch A, Ziemer M, Conrad B, Körner S, Windemuth-Kieselbach C, Schwarz L, Garbe C, Becker JC, Schadendorf D; Dermatologic Cooperative Oncology Group. Livingstone E, et al. Among authors: eigentler tk. Lancet. 2022 Oct 1;400(10358):1117-1129. doi: 10.1016/S0140-6736(22)01654-3. Epub 2022 Sep 10. Lancet. 2022. PMID: 36099927 Clinical Trial.
Loss of Pip4k2c confers liver-metastatic organotropism through insulin-dependent PI3K-AKT pathway activation.
Rogava M, Aprati TJ, Chi WY, Melms JC, Hug C, Davis SH, Earlie EM, Chung C, Deshmukh SK, Wu S, Sledge G, Tang S, Ho P, Amin AD, Caprio L, Gurjao C, Tagore S, Ngo B, Lee MJ, Zanetti G, Wang Y, Chen S, Ge W, Melo LMN, Allies G, Rösler J, Gibney GT, Schmitz OJ, Sykes M, Creusot RJ, Tüting T, Schadendorf D, Röcken M, Eigentler TK, Molotkov A, Mintz A, Bakhoum SF, Beyaz S, Cantley LC, Sorger PK, Meckelmann SW, Tasdogan A, Liu D, Laughney AM, Izar B. Rogava M, et al. Among authors: eigentler tk. Nat Cancer. 2024 Mar;5(3):433-447. doi: 10.1038/s43018-023-00704-x. Epub 2024 Jan 29. Nat Cancer. 2024. PMID: 38286827
Protein kinase inhibitors in melanoma.
Eigentler TK, Meier F, Garbe C. Eigentler TK, et al. Expert Opin Pharmacother. 2013 Nov;14(16):2195-201. doi: 10.1517/14656566.2013.827172. Epub 2013 Aug 31. Expert Opin Pharmacother. 2013. PMID: 23992377 Review.
Melanoma brain metastases - Interdisciplinary management recommendations 2020.
Gutzmer R, Vordermark D, Hassel JC, Krex D, Wendl C, Schadendorf D, Sickmann T, Rieken S, Pukrop T, Höller C, Eigentler TK, Meier F. Gutzmer R, et al. Among authors: eigentler tk. Cancer Treat Rev. 2020 Sep;89:102083. doi: 10.1016/j.ctrv.2020.102083. Epub 2020 Jul 18. Cancer Treat Rev. 2020. PMID: 32736188 Review.
151 results